24ScopeNews
πŸ‡―πŸ‡΅ ← δΈ–η•Œεœ°ε›³
Japan Times1 時間前

BioNTech lung cancer drug extends survival versus chemotherapy

BioNTech lung cancer drug extends survival versus chemotherapy

Patients treated with gotistobart lived for a median 18.5 months, compared with 10 months for those given the standard-of-care chemotherapy.

θ¨˜δΊ‹γ‚’θͺ­γ‚€ β†’

Japan Times · ✦ 24ScopeNews AI

πŸ‡―πŸ‡΅ 閒連ニγƒ₯γƒΌγ‚Ή